Baht 142.40 million or increased 20%, from Baht 707.22 million in the first half of 2017 to Baht 849.62 million compared with the same period of 2018. The main reasons for the increase were derived from
965.5 928.3 1,465.3 37.2 4.0 (499.8) (34.1) Profit for the period 61.8 72.1 123.4 (10.3) (14.3) (61.6) (49.9) In Q3–2018, the Company’s total revenue was similar to Q2–2018 with a slight increase
Performance (Income Statement) Q3.2018 Q3.2018 Increase/(decrease) % Income Income from Sale of Goods 140,004 151,554 (11,550) (7.62) Income from Sevice 81,443 - 81,443 100.00 Cost of Sale of Goods (108,549
: Million Baht Projects Consolidated Revenue Project Revenue Increase (Decrease) % Revenue (Million Baht) Revenue (Million Baht) Revenue (Million Baht) Revenue (Million Baht) 30th-Sep-19 30th-Sep-18 30th-Sep
amount to a decrease rate of 13.14 percent in 2019. The Company’s gross profit margins in 2018 – 2019 were equal to 17.14 percent and 19.89 percent, respectively. The increase in the gross profit market
period ended June 30, 2020, resulted in increase in total comprehensive income of Baht 59.64 million or 283.00% from the corresponding period of the previous year as the following details below: 1. Revenue
of following key factors: 1. Revenue from sales of electricity were THB 173 million in the third quarter of 2020, which increased by THB 81 million or 89% from the same period last year. The increase
17.74% 20.03 9.21% 49.42 246.73% Jul – Sep 63 Jul – Sep 62 Increase/(Decrease) DOD BIOTECH PUBLIC COMPANY LIMITED เลขที่ 111 หมู่ที่ 2 ตาํบลท่าจนี อาํเภอเมืองสมุทรสาคร จงัหวดัสมุทรสาคร 74000 111 Moo 2
performance in 2nd quarter and 6-month period, its cost of services amounted to Baht 21.3 million and Baht 45.4 million, a rise of 12.4% and 20.5% whereas its selling & administrative expenses enlarged at
respectively. It is a result of the construction cost increased from the previous year, which was in line with the rise of revenue. The Company's gross profit is 10% for three-month period and six-month period